Johnson and Johnson announced that its Scios unit will spend over $100 million to test the safety and effectiveness of its heart failure drug, Natrecor. The new study will involve 7,000 people and will test safety issues that arose last year when other studies showed that the drug could lead to an increased risk of kidney problems and a higher risk of mortality within the first month of treatment, when compared with other medicines.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.